Ian Birrell: Big Pharma's demise is nothing to celebrate – our health is in their hands

 

Share

You may not have heard the screams, but this was the week the drug industry fell off a cliff.

The most profitable medicine in history, which has been earning up to £8bn a year, came out of patent in the world's biggest market on Thursday. And it was just one of four bestsellers that lost protection in the United States that day.

Lipitor is the ultimate blockbuster drug, an anti-cholesterol pill that tackles the effects of modern lifestyles and helped Pfizer to be the world's biggest drug dealer. It comes out of patent across Europe in May. The company is spending a fortune to persuade patients to continue taking its medicine, but cheaper generics will savage income from this drug.

It is the most dramatic example yet of how Big Pharma is hurtling over the so-called "patent cliff", leaving the industry in a big panic. Until recently, this was the most profitable legal business on the planet; now it faces an uncertain future. It is losing control of 10 mega-medicines this year alone and dozens more over the next few years.

This is, of course, cause for celebration since it cuts the soaring costs of healthcare, which on current trends will consume more than half our GDP by the end of the century. But it is not only bean-counters who will be delighted to see pain inflicted on these behemoths.

The drug giants are almost universally hated. They are up there alongside arms manufacturers, bankers and oil firms in the pantheon of corporate evil, a villainous target for thriller writers, film-makers, polemicists and politicians. Even the Republican candidate had a pop at them in the last US presidential election.

But we need to grow up and wake up. This is one of the most important industries in Britain, and it is undergoing a technology-driven revolution as profound as those confronting the music and newspaper industries. In these tough times, we simply cannot afford hostility to "grubby" commerce, let alone our usual insouciance over science.

Big Pharma has, of course, been its own worst enemy, with a wretched history of overcharging, tainted trials and the like. But Thursday was also World Aids Day, a reminder that it was primarily this most capitalist of industries that removed the death sentence from an Aids diagnosis.

Such facts offer another dose of painful reality for those anti-capitalist protesters pitching tents at St Paul's. Indeed, for all the allegations of ripping off poor countries, the loathed big guns of the pharmaceutical industry can claim some credit for the improving health and increasing longevity of the human race across the globe.

They also play a vital role in Britain's economic health, with life sciences employing 165,000 people and more than 4,000 firms turning over £50bn a year. Two of the world's biggest drug companies are British – but they, too, are staring into the abyss. Astra-Zeneca, for example, has two drugs coming out of patent protection in the next three years that account for nearly one-third of its sales.

Big Pharma's business model is at breaking point. Not just because regulators are more risk-averse and health services demand cheaper drugs and more generics. But because they can no longer just hire tens of thousands of researchers to create new generations of blockbuster drugs that will work on vast swathes of the population, earning back the billions they cost to develop and trial.

We have moved into a new era of medicine thanks to astonishing advances in biology and genetics. Perhaps the best example is paracetamol, around since the 19th century and one of the most commonly used household drugs. But only this year have researchers at King's College London finally understood how it works on the human body, opening up the prospect of safer and more effective painkillers.

The consequence of such advances is drugs that work less like a blunderbuss and more like a sniper's rifle, aiming their medicinal bullets at smaller groups of people. So we have a drug such as Herceptin, so effective for treating breast cancer – but only for women with a particular receptor on their cancerous cells.

This technological revolution, based on complex biology rather than just firing off chemical compounds, is forcing drug companies to reinvent themselves. They are slashing research jobs – 4,500 in Britain alone in the past two years – while closing large laboratories and setting up venture capital arms to spot the next big thing.

Many of these should be found in Britain, given this country's astonishing record of scientific creativity, with more than 80 Nobel prizes – 25 claimed by Cambridge University alone – and four of the world's top 10 research universities. But can we exploit this scientific strength to remain at the forefront of the industry – or will we be left behind by hustling new players such as India, Israel and Singapore?

This issue has been greatly exercising David Cameron. He will make a speech on the subject on Monday, praising the role of life sciences and announcing new support for medical start-ups. It is a good start. But we remain locked in the past in many ways. Would he dare, for example, to allow drugs to be given to patients before the conclusion of clinical trials if there are no other treatments available, something that makes sense in a world of personalised medicines?

Or to insist that the NHS opens up access to its databases unless patients opt to keep information private? This idea is being pushed by cancer charities and would take advantage of having such a vast, centralised health system.

There also need to be cultural changes. What about funding doctors and scientists to study at business schools, as in the US? After all, in other countries experts go from academia to business and back to academia quite happily. In this country, despite improvements, the two worlds remain too far apart, with insular universities and scientists more focused on seeing ideas in print in academic journals rather than in profit in commercial ventures.

Britain needs to embrace its life scientists, who are doing such remarkable work with so little credit. But these scientists need to embrace capitalism, collaboration and to be unafraid of commerce. And we all need to embrace an unloved industry that holds the key to our future health and wealth.

twitter.com/@ianbirrell

React Now

Latest stories from i100
Have you tried new the Independent Digital Edition apps?
iJobs Job Widget
iJobs General

SAP Project Manager

competitive: Progressive Recruitment: SAP PROJECT MANAGER - 3 MONTHS - BERKSHI...

SAP Project Manager

competitive: Progressive Recruitment: SAP PROJECT MANAGER - 3 MONTHS - BERKSHI...

Senior Investment Accounting Change Manager

£600 - £700 per day + competitive: Orgtel: Senior Investment Accounting Change...

Microsoft Dynamics AX Functional Consultant

£65000 - £75000 per annum + benefits: Progressive Recruitment: A rare opportun...

Day In a Page

Read Next
Children of a bygone era  

Kids these days aren't what they used to be — they're a lot better. So why the fuss?

Archie Bland
A suited man eyes up the moral calibre of a burlesque troupe  

Be they burlesque dancers or arms dealers, a bank has no business judging the morality of its clients

John Walsh
Save the tiger: The day America’s love of backyard tigers led to a horrific bloodbath

The day America’s love of backyard tigers led to a horrific bloodbath

With only six per cent of the US population of these amazing big cats held in zoos, the Zanesville incident in 2011 was inevitable
Samuel Beckett's biographer reveals secrets of the writer's time as a French Resistance spy

How Samuel Beckett became a French Resistance spy

As this year's Samuel Beckett festival opens in Enniskillen, James Knowlson, recalls how the Irish writer risked his life for liberty and narrowly escaped capture by the Gestapo
Star Wars Episode VII is being shot on film - and now Kodak is launching a last-ditch bid to keep celluloid alive

Kodak's last-ditch bid to keep celluloid alive

Director J J Abrams and a few digital refuseniks shoot movies on film. Simon Usborne wonders what the fuss is about
Once stilted and melodramatic, Hollywood is giving acting in video games a makeover

Acting in video games gets a makeover

David Crookes meets two of the genre's most popular voices
Could our smartphones soon be diagnosing diseases via Health Kit and Google Fit?

Could smartphones soon be diagnosing diseases?

Health Kit and Google Fit have been described as "the beginning of a health revolution"
Ryanair has turned on the 'charm offensive' but can we learn to love the cut-price carrier again?

Can we learn to love Ryanair again?

Four recent travellers give their verdicts on the carrier's improved customer service
Billionaire founder of Spanx launches range of jeans that offers

Spanx launches range of jeans

The jeans come in two styles, multiple cuts and three washes and will go on sale in the UK in October
10 best over-ear headphones

Aural pleasure: 10 best over-ear headphones

Listen to your favourite tracks with this selection, offering everything from lambskin earmuffs to stainless steel
Commonwealth Games 2014: David Millar ready to serve up gold for his beloved Scotland in the end

Commonwealth Games

David Millar ready to serve up gold for his beloved Scotland in the end
UCI Mountain Bike World Cup 2014: Downhill all the way to the top for the Atherton siblings

UCI Mountain Bike World Cup

Downhill all the way to the top for the Atherton siblings
Save the tiger: The animals bred for bones on China’s tiger farms

The animals bred for bones on China’s tiger farms

The big cats kept in captivity to perform for paying audiences and then, when dead, their bodies used to fortify wine
A former custard factory, a Midlands bog and a Leeds cemetery all included in top 50 hidden spots in the UK

A former custard factory, a Midlands bog and a Leeds cemetery

Introducing the top 50 hidden spots in Britain
Ebola epidemic: Plagued by fear

Ebola epidemic: Plagued by fear

How a disease that has claimed fewer than 2,000 victims in its history has earned a place in the darkest corner of the public's imagination
Chris Pratt: From 'Parks and Recreation' to 'Guardians of the Galaxy'

From 'Parks and Recreation' to 'Guardians of the Galaxy'

He was homeless in Hawaii when he got his big break. Now the comic actor Chris Pratt is Hollywood's new favourite action star
How live cinema screenings can boost arts audiences

How live cinema screenings can boost arts audiences

Broadcasting plays and exhibitions to cinemas is a sure-fire box office smash